Betaxolol and acetazolamide. Combined ocular hypotensive effect.
To determine the combined ocular hypotensive effect of topical betaxolol hydrochloride and oral acetazolamide, we conducted a three-week clinical trial of the concurrent administration of the two drugs. One drop of betaxolol hydrochloride 0.5% every 12 hours effected a mean reduction in outflow pressure from baseline of 27.3%. When given topically to both eyes of a patient pretreated with oral acetazolamide (500 mg every 12 hours), betaxolol caused an additional mean outflow pressure decrease of 17.6%. Acetazolamide, 500 mg orally every 12 hours, produced a mean outflow pressure reduction from baseline of 42.5%. When added to the therapy regimen of a patient already receiving topical betaxolol, oral acetazolamide caused an additional mean outflow pressure decrease of 35.1%. Our study supports the clinical usefulness of concurrent administration of betaxolol and acetazolamide to lower intraocular pressure.
D000086:Acetazolamide / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001082:Aqueous Humor / Q000502:physiology; D015784:Betaxolol; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*
D009883:Ophthalmic Solutions; D011412:Propanolamines; D015784:Betaxolol; D000086:Acetazolamide